Objective: To report an 18-month follow-up on creatine and minocycline futility study, the Neuroprotective Exploratory Trials in Parkinson Disease, Futility Study 1 (NET-PD FS-1).
medications improve some of the most disabling symptoms of PD, patients accrue substantial disability over time and face a future of dependency. Thus, there is a compelling need to develop treatments that might slow down the functional decline in PD.
The National Institute of Neurological Disorders and Stroke has sponsored efforts to identify agents with the potential to favorably modify disease progression in PD. Through the Neuroprotective Exploratory Trials in Parkinson Disease (NET-PD) program, 4 agents have been evaluated, and those agents not found to be futile may be carried forward into a phase III efficacy trial. 4Y6 Creatine and minocycline were prioritized for the first study, the NET-PD Futility Study 1 (NET-PD FS-1). 4, 7 Creatine is a nutritional supplement that enhances cellular energy function and has antioxidant properties, 8 and the antibiotic minocycline has anti-inflammatory and antiapoptotic actions. 9 There is evidence that both agents can protect against the dopaminergic neuronal loss associated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) administration in a mouse model of PD, 10 although the results with minocycline are not consistent.
11Y14
In the initial futility study, 200 subjects with early untreated PD were randomly assigned in a 1:1:1 ratio to creatine (dosage, 10 g/d), minocycline (dosage, 200 mg/d), or placebo, respectively. Change in total Unified Parkinson Disease Rating Scale (UPDRS) score between baseline and 12 months or the time at which symptomatic treatment was required in each single arm was compared with a predetermined futility threshold. 15 The primary analysis at 12 months showed that the mean changes in UPDRS in the creatine and minocycline groups did not exceed the prespecified futility threshold, 4 although subsequent exploratory analyses gave more support to creatine than minocycline. 6 Although the primary futility assessment was planned for 12 months, we designed the study so that each subject would receive the treatment assignment for 18 months. The purpose of this design was to obtain additional information about the safety of the treatment interventions in subjects not yet on symptomatic therapy and in those started on symptomatic therapy. Such data would be important to take into account when considering long-term use and would be useful for the design of a later phase III trial.
METHODS
Detailed information on study organization and conduct is published in the primary article. 4 The protocol and the consent were approved by the institutional review boards of each of the participating sites, and each subject gave written informed consent. 16 and minocycline, 17, 18 we prespecified a number of adverse events, including falls, dizziness, nausea/vomiting/dyspepsia, skin reaction, headache, infection, and tooth discoloration. The relationship of an adverse event to study drug was assessed by the site investigator and the independent medical monitor and was defined as definite, probable, possible, unlikely, or not related. Laboratory assessments, including blood cell count and serum chemistry, were collected at baseline, 6, 12, and 18 months. For the 18-month assessments described in this article, UPDRS data were analyzed using descriptive statistics because the study was not designed nor powered to detect differences between treatment arms. Worst-change score for the group was used to impute missing clinical outcome values. Kaplan-Meier curves were used to estimate the time to need for symptomatic therapy. For the evaluation of the prespecified adverse events, incidence densities were computed as events per 100 person-years during the time when the subjects were receiving and were not receiving antiparkinsonian therapy. These values were adjusted for the length of time at risk (ie, time on symptomatic treatment).
RESULTS
During the 18 months of the study, 41 (61%) of 67 creatine-treated, 41 (62%) of 66 minocycline-treated, and 40 (60%) of 67 placebo-treated subjects achieved a level of disability sufficient to warrant the initiation of symptomatic treatment (Fig. 1 ). The survival curves show a similar course of development for the need of symptomatic therapy in all groups (Fig. 2) . The actual change in total UPDRS from baseline to 18 months was evaluated. Including values obtained while on symptomatic therapy, the change was 6.18 T 11.4 in the creatine group, 9.03 T 11.6 in the minocycline group, and 8.03 T 11.5 in the placebo group (Fig. 3) .
The impact of the study treatments on the clinical improvement associated with symptomatic therapy was considered by examining total UPDRS values for those subjects who required symptomatic therapy. A Box-and-Whisker plot (Fig. 4) shows the UPDRS values before initiating symptomatic therapy (at the need for symptomatic therapy visit) and at the first available visit after initiating symptomatic therapy (for those with available visits). Neither creatine nor minocycline seems to adversely affect the beneficial impact of symptomatic therapy.
There were 27 serious adverse events (SAEs) during the 18-month course of the study, 14 of which occurred during the first FIGURE 1. Flow diagram from randomization to study completion (duration, 18 months). The number of subjects terminating the study before 18 months, the number of subjects completing the study, and the number of subjects requiring symptomatic therapy are indicated. 12 months of treatment and have been reported previously. 4 For the 12-month data, 1 SAE (squamous cell carcinoma in a minocycline-treated subject) was viewed as possibly related to the study intervention by the blinded clinical site investigator. After further review by the independent medical monitor, none of the SAEs reported in the active treatment arms were thought to be definitely or probably related to the study interventions. During the subsequent 6 months, 2 SAEs occurred in the creatine group (chest pain, 2), 5 in the minocycline group (arthritis, 2; squamous cell carcinoma, *Incidence densities reported while subjects were and were not receiving symptomatic therapy. Numbers in boldface indicate increased incidence density.
1; bladder prolapse, 1; renal calculus, 1), and 6 in the placebo group (back pain, 2; chest pain, 1; abdominal adhesions, 1; male genital neoplasm, 1; and thrombophlebitis, 1). Of the SAEs in the 2 active treatment arms occurring during this additional 6 months of follow-up, none was determined to be possibly, probably, or definitely related to the study intervention by the blinded site investigator or the independent medical monitors. Throughout the 18-month course of the study, the most commonly reported adverse events across the treatment groups were nausea (19%), joint pain (25%), and upper respiratory symptoms (bronchitis, coughing, upper respiratory tract infection, sinusitis; 34%). All the nausea events occurred before 12 months, whereas joint pain and upper respiratory symptoms occurred throughout the study period. Eight cases of tooth discoloration were reported; 7 cases were in the minocycline group and occurred during the initial 12-month treatment period, and 1 case was reported in creatine group during the additional 6-month follow-up period.
To address whether adverse events were more frequent in the study participants after the initiation of symptomatic therapy, we calculated the incidence densities of adverse events during the period before symptomatic therapy and also while on symptomatic therapy. The average follow-up period was 1 year without antiparkinsonian treatment and 0.8 year with antiparkinsonian treatment. Table 1 lists the incidence densities and 95% confidence intervals (CIs) for the prespecified and for the 3 most frequently occurring adverse events. The prespecified adverse events were those adverse events known from earlier studies to be associated with at least 1 of the treatments. In general, the incidence densities are similar before and after the initiation of symptomatic treatment. The incidence density of joint pain increased from 18 to 28 (events per 100 person-years) in the creatine arm, although there was a large overlap of the 95% CIs. A similar incidence density for joint pain was present in the minocycline and placebo arms before the initiation of symptomatic therapy.
A total of 25 subjects prematurely discontinued study treatment (6 [9%] in the creatine arm, 15 [23%] in the minocycline arm, and 4 [6%] in the placebo arm). Of those receiving creatine, 5 discontinued the treatment before the initiation of symptomatic treatment and 1 after. Of those receiving minocycline, 14 discontinued the treatment before receiving symptomatic therapy, and 1 after. The 4 subjects receiving placebo who prematurely discontinued the study treatment did so before beginning symptomatic therapy.
Laboratory values were unremarkable across treatment arms except for clinically significant elevations in glucose in 5 subjects (creatine, 1; minocycline, 2; placebo, 2), alanine aminotransferase (ALT) in 3 subjects (creatine, 1; placebo, 2), and serum creatinine levels in 5 subjects (all creatine). Of these 5 subjects with elevated creatinine levels, 3 subjects had baseline creatinine values at the high range of reference value, and 1 subject had an elevated baseline creatinine level. Three of the 5 subjects permanently discontinued the administration of study drug, and the creatinine values returned to baseline. Creatinine values were elevated at the final visit in 2 subjects, and no study data were collected thereafter.
DISCUSSION
This report extends the experience of subjects in the double-blind futility trial of minocycline and creatine in early PD. 4 The present data from these small phase II studies do not raise concerns regarding the safety of either agent alone or in conjunction with medications used to treat the symptoms of PD. Moreover, neither agent seems to interfere with the beneficial effects of symptomatic therapy. A concern remains regarding the high proportion of subjects prematurely discontinuing minocycline (23%); this trend was evident early on with the use of minocycline because all but 1 subject stopped Although the study treatments were generally well tolerated and seem safe when taken during an 18-month period, it should, however, be noted that the numbers of subjects on a particular symptomatic treatment are small, and the period of follow-up on the combined treatment is variable. Additional safety concerns may arise when a larger sample is evaluated or if a sample is followed up for a longer duration. When viewing the occurrence of adverse events across treatment arms in the absence and in the presence of symptomatic therapy, there is no increase in the occurrence of adverse events associated with the introduction of symptomatic treatments, except for an increase in joint pain in those subjects on creatine. The significance of this finding is difficult to interpret given the small sample size, short follow-up period, and overlap of the CIs between the 2 groups. Although there is no evidence to suggest that creatine, in combination with therapies commonly used to treat PD, would be expected to exacerbate joint pain, the increased incidence density in this small sample suggests that monitoring for this adverse event is warranted if future studies are conducted. The finding that the adverse event profile is not significantly altered after the introduction of symptomatic therapy also suggests that subjects with more severe PD tolerate the study agents as well as those earlier in their disease course not yet requiring symptomatic therapy. However, it must be noted that those subjects on symptomatic therapy could not, by definition, have as much follow-up and, thus, as much chance to experience an adverse event. Although incidence densities were determined to adjust for this unequal follow-up, this computation does not adjust for the difference in disease severity and likelihood that those with more advanced disease may be more likely to experience an adverse event. Yet, such a difference in adverse events was not noted despite the difference in disease severity. It is also possible that symptomatic therapy may improve quality of life to the extent that fewer adverse events were reported. In addition, only 1 subject each in the creatine and minocycline groups prematurely discontinued study treatment after the introduction of symptomatic therapy, suggesting that the addition of symptomatic therapy is well tolerated. However, the ability to detect such differences is limited by the shorter exposure times with symptomatic treatment. It is thus possible that we may have missed adverse effects that would be detected in a larger, longer-term study. Although creatinine levels were found to be elevated in a subset of subjects in the creatine arm, the use of creatine has not been associated with renal dysfunction, 19 and levels returned to baseline in the 3 subjects who discontinued creatine treatment in the present study.
Estimates of the time to need symptomatic therapy do not differ between the groups. By the end of 18 months, 60% of all patients needed symptomatic therapy. On the other hand, looking at the change from baseline in total UPDRS score (actual change; Fig. 3) , there seems to be the beginnings of a separation between the groups, although the study was not powered to detect such differences. These data suggest that a longer period of follow-up may be required to determine treatment differences. The reduction in total UPDRS score after initiation of symptomatic therapy is similar to that observed in earlier studies. 20 The results of this study suggest that both creatine and minocycline seem safe when taken over an 18-month period. These agents do not seem to influence the response to symptomatic therapy, and the introduction of symptomatic therapy is not associated with a worrisome increase in adverse events. However, the tolerability of minocycline may be of concern when considering a long-term study where even moderate withdrawal occurring early on could dilute the ability to detect a treatment effect. In addition, the sample size in the present study was small, and it cannot be concluded that safety concerns may not arise in a larger sample studied for a longer duration.
